GH Axis · Placeholder catalog data
Tesamorelin
Also known as TH9507
A synthetic analog of human GHRH(1-44) stabilized by N-terminal trans-3-hexenoic acid. Approved as Egrifta for HIV-associated lipodystrophy and widely studied in visceral adipose tissue research.
190 credits
Paid from your credit pool at checkout. Bulk quantities discount automatically.
Available variants
Pricing and fulfillment information is placeholder data.
| Amount | SKU | Credits | MSRP | Availability | Margin estimate |
|---|---|---|---|---|---|
| 5 mg | PTS-TES-5 | 38 credits | $79 | Ready | 52% estimate |
| 10 mg | PTS-TES-10 | 51 credits | $129 | Ready | 60% estimate |
Margin estimate treats 1 credit as $1 and compares estimated wholesale credit cost with placeholder MSRP. It excludes shipping, taxes, and other costs.
Buy more, save more
Quantity breaks apply per line item and are deducted automatically at checkout.
| Quantity per line | Discount | Example (5 mg unit) |
|---|---|---|
| 10+ units | 5% off | 10 × 38 credits → 361 credits |
| 25+ units | 10% off | 25 × 38 credits → 855 credits |
| 50+ units | 15% off | 50 × 38 credits → 1,615 credits |
| 100+ units | 20% off | 100 × 38 credits → 3,040 credits |
Specifications
- CAS
- 218949-48-5
- Formula
- C223H346N44O69S
- Molecular weight
- 5135.85 g/mol
- Sequence
- trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
- Purity
- ≥99%
- Appearance
- White lyophilized powder
- Storage
- Store lyophilized at −20 °C, protected from light and moisture
Quality record
COA status
COA listedLot PTS-TES-2607
Placeholder reference. Verify the active lot before ordering.
Research background
Tesamorelin is a stabilized 44-amino-acid analog of human growth hormone releasing hormone. A trans-3-hexenoic acid modification at the N-terminus confers resistance to enzymatic degradation and extends circulating half-life in published pharmacokinetic studies.
Tesamorelin is FDA-approved as Egrifta® for HIV-associated lipodystrophy, where clinical literature has documented reductions in visceral adipose tissue. In broader research contexts, the peptide is studied as a tool for examining GH/IGF-1 axis modulation and ectopic fat deposition.
Supplied exclusively as a research reagent.
Mechanism: Literature describes Tesamorelin as a long-acting GHRH receptor agonist acting on anterior pituitary somatotrophs to stimulate endogenous GH secretion.
Research use only
For research use only. Not for human or veterinary use.